Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs

ResearchMoz added Latest Research Report titled " Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs - Markets and Research " to it's Large Report database.

Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The gastric cancer market is undergoing a gradual change, from a focus on generic chemotherapy regimens to complex treatment landscape based on targeted therapies. Recently the market has witnessed the approval of efficacious therapies such as Cyramza, but this only benefits a small subset of patients. As the understanding of disease pathophysiology increases, new targets need to be identified and converted into improved therapeutic options. The current pipeline shows strong promise, as it shows a gradual shift from generic cytotoxic therapies to more diverse targeted therapies.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=713902

Scope

• What is the pathophysiology of gastric cancer?
• How is gastric cancer diagnosed?
• What are the current treatment options?
• What are the common targets and mechanisms of action of pipeline therapies?
• Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer patients?
• What implications will the increased focus on targeted therapies have on the future of gastric cancer treatment?
• What are the most promising first-in-class targets for gastric cancer?
• Will the current first-in-class targets have a broader therapeutic potential across the industry?
• How do deal frequency and value compare between target families and molecule types?
• How do licensing and co-development deals compare between first-in-class and non-first-in-class profiles?

Read All Gastric Cancer Market Research Reports @ http://www.researchmoz.us/Gastric-Cancer-market-reports-22.html

Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 4
2.1 Significant Unmet Needs in the Gastric Cancer Market 4
2.2 High Proportion of First-in-Class Innovation Offers Promise in Gastric Cancer 4
2.3 Deal Activity Varies with First-in-Class Status 4

3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Development Remains Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report Guidance 8

4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.2 Disease Symptoms 9
4.3 Epidemiology and Etiology 9
4.4 Pathophysiology 9
4.4.1 Helicobacter Pylori 10
4.4.2 Oncogenes 10
4.4.3 Tumor Suppressor Genes 10
4.4.4 Cell Adhesion Molecules and Metastasis-Related Genes 10
4.4.5 Cell Cycle Regulators 10

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG